Literature DB >> 23483495

Comparing treatment options of pterygium: limbal sliding flap transplantation, primary closing, and amniotic membrane grafting.

Sevda Aydin Kurna1, Ahmet Altun, Bahtinur Aksu, Riza Kurna, Tomris Sengor.   

Abstract

OBJECTIVE: To compare 3 surgical treatment options of pterygium: limbal sliding flap transplantation, primary closing, and amniotic membrane grafting methods.
METHODS: Seventy-five patients with primary pterygium were included in the study. Snellen visual acuity measurement, grading pterygium, slit-lamp examination, keratometry, and anterior segment photography were performed preoperatively. Twenty-eight eyes of 28 patients (group 1) underwent limbal-conjunctival sliding flap transplantation, 22 eyes of 22 patients (group 2) underwent amniotic membrane grafting, and 25 eyes of 25 patients (group 3) underwent primary closing surgery. The patients were followed up on the first day and the first week after surgery and then at months 1, 3, 6, and 12.
RESULTS: The mean size of the pterygium preoperatively was 3.58 ± 1.1 mm in group 1, 3.95 ± 0.90 mm in group 2, and 3.5 ± 0.87 mm in group 3. The mean follow-up time was 15.07 ± 13.8 months in group 1, 20.2 ± 6.7 months in group 2, and 28.04 ± 9.9 months in group 3. Grade 4 corneal recurrence rate in follow-up was 7.1% in group 1, 27.3% in group 2, and 56% in group 3 (p = 0.00). Mean recurrence times were 4.0 ± 1.7, 4.4 ± 3.3, and 4.4 ± 3.6 months according to groups 1, 2, and 3 (p = 0.963). After the surgery, corneal astigmatism decreased and keratometric values increased significantly in all the groups with no statistically significant difference between the groups (p>0.05).
CONCLUSION: Limbal-conjunctival sliding flap transplantation is an efficient method to manage primary pterygium. It may be a safe and effective initial treatment option to reduce risk of recurrence and postoperative complications of pterygium surgery.

Entities:  

Mesh:

Year:  2013        PMID: 23483495     DOI: 10.5301/ejo.5000263

Source DB:  PubMed          Journal:  Eur J Ophthalmol        ISSN: 1120-6721            Impact factor:   2.597


  8 in total

1.  Resolution of Corneal Dellen After an Uneventful Pterygium Surgery with Punctal Cautery.

Authors:  Bharti Sharma; Sushil Kumar Bajoria; Abhishek Patnaik; Ravi Barbhaya
Journal:  Cureus       Date:  2020-05-23

2.  A novel graft option after pterygium excision: platelet-rich fibrin for conjunctivoplasty.

Authors:  H B Cakmak; G Dereli Can; M E Can; N Cagil
Journal:  Eye (Lond)       Date:  2017-06-16       Impact factor: 3.775

3.  Characteristics and recurrence of pterygium in Saudi Arabia: a single center study with a long follow-up.

Authors:  Waleed Alsarhani; Saeed Alshahrani; Mahmood Showail; Nawaf Alhabdan; Osama Alsumari; Abdullah Almalki; Abdulaziz Alsarhani; Adel Alluhaidan; Bader Alqahtani
Journal:  BMC Ophthalmol       Date:  2021-05-11       Impact factor: 2.209

4.  Non-Recurrence Complications of Fibrin Glue Use in Pterygium Surgery: Prevention and Management.

Authors:  Halil Hüseyin Cagatay; Gökçen Gökçe; Alper Mete; Yaran Koban; Metin Ekinci
Journal:  Open Ophthalmol J       Date:  2015-11-04

5.  Evaluation of Topical Lignocaine Jelly 2% for Recurrent Pterygium Surgery with Glue-free Autologous Conjunctival Graft.

Authors:  Rajesh Subhash Joshi
Journal:  Middle East Afr J Ophthalmol       Date:  2017 Jul-Sep

6.  Efficacy and Safety of Amniotic Membrane Transplantation Combined with Closure of Tenon Capsule and Bulbar Conjunctival Space in the Treatment of Primary Pterygium.

Authors:  Jingyao Chen; Yixin Zheng; Weijia Zhang; Zijun Zhao; Yanze Xu
Journal:  Contrast Media Mol Imaging       Date:  2022-09-02       Impact factor: 3.009

Review 7.  The use of dry amniotic membrane in pterygium surgery.

Authors:  Gelareh S Noureddin; Sonia N Yeung
Journal:  Clin Ophthalmol       Date:  2016-04-18

8.  Recurrence Rate and Clinical Outcome of Amniotic Membrane Transplantation Combined with Mitomycin C in Pterygium Surgery: Two-Year Follow-Up.

Authors:  Hasan Razmjoo; Seyed-Abolfazl Kashfi; Majid Mirmohammadkhani; Mohsen Pourazizi
Journal:  J Res Pharm Pract       Date:  2020-03-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.